GlobeNewswire

Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
12/11/2026
Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the first half of 2027 LOS ANGELES, Nov. 12, 2026 ( [...]
Jushi Holdings Inc. Announces Opening of Relocated Beyond Hello™ Dispensary in Hamburg, Pennsylvania
12/11/2026
BOCA RATON, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ) , a vertically integrated, multi-state cannabis operator, today announced the opening of [...]
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
12/11/2026
On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027 Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 2027 with over 500 patients, up [...]
Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)
12/11/2026
FORT WORTH, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and [...]
Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
12/11/2026
Dallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at [...]
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
12/11/2026
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on [...]
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
12/11/2026
— Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement — — Interim NEXICART-2 clinical [...]
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
12/11/2026
Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth Jemperli approved in the U.S. as the first and only immunotherapy for adults [...]
BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12/11/2026
KUALA LUMPUR, MALAYSIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
12/11/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 12 nov. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
12/11/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 12, 2026 (GLOBE NEWSWIRE [...]
InspireMD Announces Proposed Public Offering
12/11/2026
MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it has [...]
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/11/2026
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
12/11/2026
– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million – – Enrollment completed in the first [...]
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
12/11/2026
SUNNYVALE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
12/11/2026
– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 – Dosing initiated in Cohort 2 of the registrational study ; topline single-ascending-dose data expected in [...]
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
12/11/2026
Submission is based on Phase 3 REZILIENT3 data in first-line EGFR ex20ins NSCLC CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company [...]
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
12/11/2026
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared updated long-term efficacy data for both relutrigine and ulixacaltamide [...]
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
12/11/2026
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 – – STRO-006, ITGB6-targeting ADC, enters clinic with first patient [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum